Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
Retrieved on:
星期四, 五月 9, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, MSD, B21, Radiation, DFS, Paclitaxel, Food, Merck & Co., Immunotherapy, Eisai, Data monitoring committee, Rated R, PDUFA, ADC, Patient, Endometrial cancer, Cancer, MSI-H, Carboplatin, MRK, Pharmaceutical industry
The study’s other primary endpoint of overall survival (OS) was not formally tested since superiority was not reached for DFS.
Key Points:
- The study’s other primary endpoint of overall survival (OS) was not formally tested since superiority was not reached for DFS.
- The safety profile of KEYTRUDA was consistent with that observed in previously reported studies; no new safety signals were identified.
- Merck will work with investigators to share the results with the scientific community.
- “We would like to thank all the patients, the investigators and our study collaborators for their participation in this trial.”
In the U.S., KEYTRUDA has two approved indications in endometrial cancer.